Aptevo Therapeutics (NASDAQ:APVO) Shares Cross Below 50-Day Moving Average – Here’s What Happened

Aptevo Therapeutics Inc. (NASDAQ:APVO)’s share price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $4.69 and traded as low as $4.41. Aptevo Therapeutics shares last traded at $4.55, with a volume of 17,385 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on APVO. Weiss Ratings upgraded Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Aptevo Therapeutics Stock Performance

The company has a market capitalization of $6.19 million, a PE ratio of -0.03 and a beta of 1.64. The company has a 50 day moving average price of $4.69 and a 200 day moving average price of $10.76.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($6.41). On average, equities analysts forecast that Aptevo Therapeutics Inc. will post -24.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.